Literature DB >> 17607801

Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study.

Martin Steinberg1, Huibo Shao, Peter Zandi, Constantine G Lyketsos, Kathleen A Welsh-Bohmer, Maria C Norton, John C S Breitner, David C Steffens, Joann T Tschanz.   

Abstract

BACKGROUND: Neuropsychiatric symptoms are nearly universal in dementia, yet little is known about their longitudinal course in the community.
OBJECTIVE: To estimate point and 5-year period prevalence of neuropsychiatric symptoms in an incident sample of 408 dementia participants from the Cache County Study.
METHODS: The Neuropsychiatric Inventory assessed symptoms at baseline and at 1.5 years, 3.0 years, 4.1 years, and 5.3 years. Point prevalence, period prevalence and mean symptom severity at each time point were estimated.
RESULTS: Point prevalence for delusions was 18% at baseline and 34-38% during the last three visits; hallucinations, 10% at baseline and 19-24% subsequently; agitation/aggression fluctuated between 13% and 24%; depression 29% at baseline and 41-47% subsequently; apathy increased from 20% at baseline to 51% at 5.3 years; elation never rose above 1%; anxiety 14% at baseline and 24-32% subsequently; disinhibition fluctuated between 2% and 15%; irritability between 17% and 27%; aberrant motor behavior gradually increased from 7% at baseline to 29% at 5.3 years. Point prevalence for any symptom was 56% at baseline and 76-87% subsequently. Five-year period prevalence was greatest for depression (77%), apathy (71%), and anxiety (62%); lowest for elation (6%), and disinhibition (31%). Ninety-seven percent experienced at least one symptom. Symptom severity was consistently highest for apathy.
CONCLUSIONS: Participants were most likely to develop depression, apathy, or anxiety, and least likely to develop elation or disinhibition. Give converging evidence that syndromal definitions may more accurately capture neuropsychiatric co-morbidity in dementia, future efforts to validate such syndromes are warranted. Copyright (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2008        PMID: 17607801      PMCID: PMC2932652          DOI: 10.1002/gps.1858

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  22 in total

1.  APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study.

Authors:  J C Breitner; B W Wyse; J C Anthony; K A Welsh-Bohmer; D C Steffens; M C Norton; J T Tschanz; B L Plassman; M R Meyer; I Skoog; A Khachaturian
Journal:  Neurology       Date:  1999-07-22       Impact factor: 9.910

2.  Pharmacological treatment of neuropsychiatric symptoms of dementia.

Authors:  Martin Steinberg; Constantine Lyketsos
Journal:  JAMA       Date:  2005-05-11       Impact factor: 56.272

3.  The course of neuropsychiatric symptoms in dementia. Part I: findings from the two-year longitudinal Maasbed study.

Authors:  Pauline Aalten; Marjolein E de Vugt; Niek Jaspers; Jaspers Jolles; Frans R J Verhey
Journal:  Int J Geriatr Psychiatry       Date:  2005-06       Impact factor: 3.485

4.  The General Medical Health Rating: a bedside global rating of medical comorbidity in patients with dementia.

Authors:  C G Lyketsos; E Galik; C Steele; M Steinberg; A Rosenblatt; A Warren; J M Sheppard; A Baker; J Brandt
Journal:  J Am Geriatr Soc       Date:  1999-04       Impact factor: 5.562

5.  Neuropsychiatric symptoms and quality of life in Alzheimer disease.

Authors:  Il-Seon Shin; Michele Carter; Donna Masterman; Lynn Fairbanks; Jeffrey L Cummings
Journal:  Am J Geriatr Psychiatry       Date:  2005-06       Impact factor: 4.105

6.  The impact of neuropsychiatric symptoms of dementia on distress in family and professional caregivers in Singapore.

Authors:  Lay Ling Tan; Hwee Bee Wong; Harry Allen
Journal:  Int Psychogeriatr       Date:  2005-06       Impact factor: 3.878

7.  Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium.

Authors:  Philippe H Robert; Frans R J Verhey; E Jane Byrne; Catherine Hurt; Peter Paul De Deyn; Flavio Nobili; Roberta Riello; Guido Rodriguez; Giovanni B Frisoni; Magda Tsolaki; Nora Kyriazopoulou; Roger Bullock; Alistair Burns; Bruno Vellas
Journal:  Eur Psychiatry       Date:  2005-01-27       Impact factor: 5.361

8.  Behaviour changes in dementia. 2: Are there behavioural syndromes?

Authors:  T Hope; J Keene; C Fairburn; R McShane; R Jacoby
Journal:  Int J Geriatr Psychiatry       Date:  1997-11       Impact factor: 3.485

9.  Behavioral syndromes in Alzheimer's disease: description and correlates.

Authors:  G B Frisoni; L Rozzini; A Gozzetti; G Binetti; O Zanetti; A Bianchetti; M Trabucchi; J L Cummings
Journal:  Dement Geriatr Cogn Disord       Date:  1999 Mar-Apr       Impact factor: 2.959

10.  Behavioural and psychological syndromes in Alzheimer's disease.

Authors:  A Mirakhur; D Craig; D J Hart; S P McLlroy; A P Passmore
Journal:  Int J Geriatr Psychiatry       Date:  2004-11       Impact factor: 3.485

View more
  176 in total

1.  Prevalence of neuropsychiatric symptoms in CIND and its subtypes: the Cache County Study.

Authors:  Matthew E Peters; Paul B Rosenberg; Martin Steinberg; JoAnn T Tschanz; Maria C Norton; Kathleen A Welsh-Bohmer; Kathleen M Hayden; John C S Breitner; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2012-05       Impact factor: 4.105

2.  The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.

Authors:  P B Rosenberg; M M Mielke; D Han; J S Leoutsakos; C G Lyketsos; P V Rabins; P P Zandi; J C S Breitner; M C Norton; K A Welsh-Bohmer; I H Zuckerman; G B Rattinger; R C Green; C Corcoran; J T Tschanz
Journal:  Int J Geriatr Psychiatry       Date:  2012-02-29       Impact factor: 3.485

3.  Incidence and predictive factors of depressive symptoms in Alzheimer's disease: the REAL.FR study.

Authors:  C Arbus; V Gardette; C E Cantet; S Andrieu; F Nourhashémi; L Schmitt; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-08       Impact factor: 4.075

4.  Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction.

Authors:  Paul B Rosenberg; Michelle M Mielke; Brian Appleby; Esther Oh; Jeannie-Marie Leoutsakos; Constantine G Lyketsos
Journal:  Int J Geriatr Psychiatry       Date:  2010-09-15       Impact factor: 3.485

5.  Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)?

Authors:  Lea T Drye; Barbara K Martin; Constantine E Frangakis; Curtis L Meinert; Jacobo E Mintzer; Cynthia A Munro; Anton P Porsteinsson; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; Daniel Weintraub; Constantine G Lyketsos
Journal:  Int J Geriatr Psychiatry       Date:  2011-06       Impact factor: 3.485

6.  Citalopram for agitation in Alzheimer's disease: design and methods.

Authors:  Lea T Drye; Zahinoor Ismail; Anton P Porsteinsson; Paul B Rosenberg; Daniel Weintraub; Christopher Marano; Gregory Pelton; Constantine Frangakis; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; D P Devanand; Jerome Yesavage; Jacobo E Mintzer; Lon S Schneider; Bruce G Pollock; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2012-02-01       Impact factor: 21.566

7.  Behavioral disturbance in dementia.

Authors:  Abhilash K Desai; Lori Schwartz; George T Grossberg
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

8.  Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.

Authors:  Paul B Rosenberg; Krista L Lanctôt; Lea T Drye; Nathan Herrmann; Roberta W Scherer; David L Bachman; Jacobo E Mintzer
Journal:  J Clin Psychiatry       Date:  2013-08       Impact factor: 4.384

9.  Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer's disease.

Authors:  Paula T Trzepacz; Peng Yu; Phani K Bhamidipati; Brian Willis; Tammy Forrester; Linda Tabas; Adam J Schwarz; Andrew J Saykin
Journal:  Alzheimers Dement       Date:  2012-12-17       Impact factor: 21.566

10.  Mild cognitive impairment: searching for the prodrome of Alzheimer's disease.

Authors:  Paul B Rosenberg; Constantine Lyketsos
Journal:  World Psychiatry       Date:  2008       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.